Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Launches Expanded Access Program For Molgramostim in aPAP Patients
Details : Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 27, 2024
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $100.0 million
Deal Type : Public Offering
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Details : The net proceeds will be used to fund the clinical development and approval of molgramostim, which is being evaluated in the treatment of autoimmune pulmonary alveolar proteinosis.
Brand Name : Molgradex
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 28, 2024
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Reports Molgramostim Achieved Significance in Phase 3 IMPALA-2 Trial for aPAP
Details : Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 26, 2024
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molgramostim
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $80.0 million
Deal Type : Public Offering
Details : The net proceeds will be used for the development of molgramostim nebulizer solution, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : Molgramostim
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $80.0 million
Deal Type : Public Offering
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 26, 2023
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
Details : Data demonstrated that patients treated with molgramostim after undergoing WLL had greater improvements in endpoint measures of gas exchange, including alveolar-arterial oxygen difference and diffusing capacity of the lungs for carbon monoxide corrected ...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 06, 2022
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP...
Brand Name : Molgramostim
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 20, 2022
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Silicon Valley Bank
Deal Size : Undisclosed
Deal Type : Financing
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
Details : Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer Syste...
Brand Name : rhGM-CSF
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 22, 2022
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Silicon Valley Bank
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Provides Pipeline and Business Update
Details : The Company announced that the Phase 3 trial of AeroVanc (vancomycin hydrochloride inhalation powder) in people living with cystic fibrosis (CF) who have Methicillin-resistant Staphylococcus aureus (MRSA) lung infection did not meet the primary endpoint.
Brand Name : AeroVanc
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2020
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molgramostim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company has decided to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF).
Brand Name : Molgradex
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 03, 2020
Lead Product(s) : Molgramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?